Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Concert Pharmaceuticals

Concert Pharmaceuticals?uq=UG6efJS6
2006 FOUNDED
PUBLIC STATUS
61-70 EMPLOYEES
CNCE STOCK SYMBOL
$14.84 SHARE PRICE (As of Friday Closing)
Description

Developer of bio-pharmaceutical drugs designed to address unmet patient needs. The company develops novel, small-molecule drugs, utilizing DCE (deuterated chemical entity) platform, approved drugs, advanced clinical candidates or previously studied compounds that can be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy, targeting central nervous system (CNS) disorders, renal disease, inflammation and cancer.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 99 Hayden Avenue
  • Suite 500
  • Lexington, MA 02421
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Concert Pharmaceuticals’s full profile, request a free trial.

Concert Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$12.82 - $29.05 $357M $15.23 $4.56 133K 23.4M

Concert Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 193,594 382,015 121,210 279,299
Revenue 154,337 143,891 174 66,729
EBITDA 105,215 97,162 (49,827) 25,697
Net Income 104,211 95,639 (50,720) 24,174
Total Assets 220,515 211,736 100,395 146,932
Total Debt 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Concert Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Concert Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Concert Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Concert Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Concert Pharmaceuticals Executive Team (6)

Name Title Board
Seat
Contact
Info
Roger Tung Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Marc Becker Chief Financial Officer
Nancy Stuart Chief Operating Officer
James Cassella Ph.D Chief Development Officer
Ian Silverman Ph.D Senior Vice President & General Counsel

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »

Concert Pharmaceuticals Board Members (10)

Name Representing Role Since Contact
Info
Peter Hutt Self Board Member 000 0000
Richard Aldrich Self Co-Founder & Chairman 000 0000
Roger Tung Ph.D Concert Pharmaceuticals Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Ronald Barrett Ph.D Self Board Member 000 0000

6 Former Board Members

You’re viewing 4 of 10 board members. Get the full list »